The Global Generics & Biosimilars Awards 2020 are taking place as a digital event on Tuesday 3 November 2020, with an entry deadline date of 14 August 2020. (Also see "The Global Generics & Biosimilars Awards 2020 Is Going Digital" - Generics Bulletin, 6 July, 2020.)
Video Podcast: The Global Generics & Biosimilars Awards 2020
Everything You Need To Know About This Year’s Digital Event
Hear all the details of the Global Generics & Biosimilars Awards 2020, now taking place on 3 November as a digital event, with a newly-extended entry deadline date of 14 August.
More from Generics
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
As Indian CROs are bracing for new registration mandates, an expert panel at the IGBA’s 3rd Bioequivalence conference discusses the implications of non-compliance in bioequivalence studies.
• By
Speaking as Hypera delivered its full year-results, CEO Breno Oliveira has set out plans for the Brazilian firm to launch an Ozempic rival in its domestic market next year. Meanwhile, the company is dealing with increasingly aggressive local generic competition.
• By
Complaints from UK originator association the ABPI over rising payments required by the country’s voluntary scheme for branded medicines pricing have been denounced by the BGMA, which says the differentiated scheme is “delivering precisely as it was intended.”
More from Products
• By
Alvotech and Advanz have announced a UK MHRA filing acceptance for their partnered AVT23 proposed biosimilar to Xolair (omalizumab).
• By
Optum Rx, one of the largest PBMs in the US, declared itself as the “first comprehensive, transparent pharmacy services company” after announcing several consumer-friendly changes.
• By
With an ambitious goal to file a biosimilar to the world-renowned Botox brand via the US FDA’s 351(k) regulatory pathway, AEON Biopharma has revealed the latest steps in its plan.